The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.
not least the serious inconvenience for those afflicted with chronic bowel problems, notably the diarrhoea-predominant form of irritable bowel syndrome. Gratifyingly, this may be less of an issue than ...
China NMPA approves Sanofi & Regeneron’s Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD: Paris Monday, September 30, 2024, 11:00 Hrs [IST] The Nat ...
Sufferers of the disease experience an extreme immune reaction after eating the protein, causing a host of symptoms including nutrient deficiencies, chronic diarrhea, nausea and agonizing pain. Many ...
UCB, a global biopharmaceutical company, today announced the start of BE BOLD, a head-to-head Phase 3b study, comparing BIMZELX® (bimekizumab-bkzx), an interleukin (IL)-17A and IL-17F inhibitor, with ...